Spi13 Inhibitors
Spiroindolines, commonly abbreviated as Spi13, form a class of chemical inhibitors characterized by their unique spirocyclic indoline framework. This structural motif comprises a bicyclic system in which a spiro carbon atom is shared between an indoline ring and another carbon-based ring, which can vary in size. The 13 in Spi13 is generally a reference to a specific target or series within the spiroindoline class, denoting a particular structural variant or a defined set of substitutions that modulate the chemical properties of these compounds. The spiroindoline core is known for its rigid structure, which can confer a high degree of specificity in its interactions with various molecular targets. This rigidity is a result of the spiro linkage that locks the rings in place, reducing the conformational flexibility typically observed in non-spirocyclic compounds.
Spi13 inhibitors are synthesized through a range of synthetic organic chemistry techniques, which often involve the formation of the spiro bond as a key step. This can be achieved through methods such as intramolecular cyclization reactions, where a preformed indoline derivative undergoes a transition state leading to the spirocyclic structure. The fine-tuning of Spi13 inhibitors involves modifying the indoline moiety or the additional cyclic structure to attain desirable physicochemical properties. The substituents on the Spi13 framework can vary widely, including but not limited to, alkyl, aryl, heteroaryl, alkoxy, and halogen groups. Such modifications can drastically influence the binding affinity and selectivity of Spi13 inhibitors by altering factors like molecular geometry, electronic distribution, and steric hindrance. As with many classes of chemical inhibitors, the design and synthesis of Spi13 compounds are often guided by detailed structure-activity relationship (SAR) studies, which help in understanding how various chemical modifications impact the interaction of these molecules with their target sites.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Xanthohumol from hop (Humulus lupulus) | 6754-58-1 | sc-301982 | 5 mg | $361.00 | 1 | |
Xanthohumol is a prenylated flavonoid from hops that inhibits NF-κB signaling. Spi13 activity is influenced by NF-κB, as NF-κB can regulate the expression of genes relevant to Spi13's function. Inhibition of NF-κB by xanthohumol would thus indirectly lead to decreased activation of Spi13. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor known to block the MAPK/ERK pathway. Spi13, when involved in cellular processes moderated by the MAPK pathway, would have reduced activity as a consequence of the pathway's inhibition, due to decreased downstream signaling events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that disrupts the PI3K/AKT pathway. Since Spi13's function can be impacted by PI3K/AKT pathway activity, the inhibition of PI3K would indirectly reduce the functional activity of Spi13 by attenuating the pathway's signaling leading to Spi13 activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), which is involved in stress and inflammatory responses. Spi13 activity can be modulated by JNK signaling; thus, its inhibition could lead to a decrease in Spi13 activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor, and the p38 MAPK pathway is implicated in the regulation of pro-inflammatory cytokines and stress responses. Inhibition of this pathway by SB203580 would lead to an indirect decrease in Spi13 activity, as Spi13 may be involved in related cellular responses. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of MAPK/ERK. By inhibiting MEK, U0126 reduces the activation of the ERK pathway, which could result in a decreased activity of Spi13, assuming Spi13 is regulated through this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, which plays a role in various cellular processes, including cell growth and survival. By inhibiting PI3K, Wortmannin could indirectly affect Spi13 activity by hindering the signaling events that lead to its activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can suppress cell growth and proliferation. Since Spi13's function could be tied to mTOR signaling, the use of Rapamycin might lead to decreased Spi13 activity by inhibiting related signaling pathways. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of protein substrates involved in various signaling pathways. By blocking proteasomal degradation, MG132 could increase the levels of proteins that negatively regulate Spi13, thereby indirectly decreasing its activity. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide is an inhibitor of dihydroorotate dehydrogenase (DHODH) and has anti-proliferative properties. It can lead to decreased pyrimidine synthesis, which may indirectly affect Spi13 by reducing the resources necessary for its function in rapidly dividing cells. | ||||||